Liver disease patent portfolio up for sale

Nevada, USA-based IpAuctions will auction the worldwide biotherapeutic patents previously owned by Cell Works, a Maryland-based biotechnology company, and acquired by CellPoint Diagnostics, based in Mountain View, California. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.

15 major US and worldwide medical patents and applications in three major treatment areas will be auctioned, including one associated with a liver cancer therapeutic drug that has been granted orphan drug status by the Food and Drug Administration. The worldwide market for a liver cancer therapeutic is quite large, however, and US Orphan Drug status includes other possible benefits such as research grants, assistance in negotiating the regulatory process and special tax credits. The IP portfolio currently for sale by IpAuctions consists of a therapeutic platform for a ligand-directed drug delivery system that can target the liver or the renal system for greater specificity and efficacy, with less toxicity to the patient.